Aim: To examine the generalizability of results from glucagon-like peptide-1 receptor agonist (GLP-1 RA) cardiovascular outcome trials (CVOTs) in the US type 2 diabetes (T2D) population.
| INTRODUCTION
Cardiovascular disease is the leading cause of morbidity and mortality for individuals with diabetes. 1 To address this concern, in 2008 the U.S. Food and Drug Administration (FDA) issued guidelines for the pharmaceutical industry suggesting sponsors show that any new therapy for type 2 diabetes (T2D) will not result in an unacceptable increase in cardiovascular risk. 2 According to these FDA guidelines, Phase 2 and Phase 3 trials should examine cardiovascular events, including cardiovascular mortality, myocardial infarction (MI), and stroke, and be designed to facilitate the performance of a metaanalysis at completion. 2 In practice, cardiovascular outcome trials (CVOTs) are subsequently conducted in order for the drug to continue to be available to patients. 3 In response to this guidance, new T2D drug therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are being tested in CVOTs. Because the designs of these trials favour enrolment of patients with unusually high cardiovascular risk, including some with prior cardiovascular events or renal disease, it is unclear whether the results are applicable to the majority of patients with T2D who have no more than moderate risk of developing cardiovascular complications. 4 We therefore evaluated the extent to which the populations of patients enrolled in GLP-1 RA trials of agents used in the United
States, or eligible to be enrolled, reflect the general population of adult patients with T2D.
2 | METHODS
| Databases
The primary source for representative US data was IQVIA Real World it may not perfectly reflect the distribution of the general population. 5, 6 Information on age and sex of individuals with T2D from the 2013 to 2014 National Health and Nutrition Examination Survey (NHANES) 7 was therefore applied to the IQVIA data in order to more accurately represent all adults with T2D. This was conducted in the following fashion. First, adults with T2D in the NHANES database were identified using published algorithms, [8] [9] [10] and NHANES sampling weights for this population were saved to provide an unbiased representation of the US Census civilian non-institutionalized population. and to have a cardiovascular outcome as the primary endpoint.
| Analyses
The generalizability of findings from these CVOTs was examined in two ways. First, the participants actually enrolled into the trials were Table 1 lists the key I/E criteria and Supporting Information Appendix B provides a detailed summary of how the cardiovascular criteria for each of the studies were mapped to our retrospective population.
| RESULTS
The CVOT study search criteria identified four clinical trials: EXSCEL Proportion of patients with established cardiovascular disease is provided in the original study protocol. However, the amended protocol changes this to "approximately 70%". Use of the original protocol percentage will bias the estimate of the generalizability of EXSCEL upward. b The trial also excluded insulin other than human NPH insulin or long-acting analogue within 3 months prior to screening. However, since they allowed for short-term use of insulin for intercurrent illness at investigator discretion, we did not use this criterion. Data provided as means and interquartile ranges were converted to means and standard deviations assuming a normal distribution. 25 percentage of patients in the reference population who were similar to those enrolled in the REWIND trial exceeded those in the other CVOTs examined when two or more of the six enrolment criteria had to be met (Supporting Information Appendix C). 
| Analysis based on the enrolled populations

| Analysis based on inclusion and exclusion criteria
| Sensitivity analysis
Similar results were noted when the analyses were repeated for the 113 074 patients in the IQVIA database without any adjustment to match the US T2D population in age and sex (Supporting Information Appendices D1-D3). A quantitative analysis of the percentages of the general population matching those in the trial populations with regard to enrolment characteristics suggested differences among these groups. The analysis of the percentages of the general population matching those actually enrolled in the trials indicated that~75% of the general population was represented by participants enrolled in SUSTAIN-6 with respect to renal function, compared with~95% to 100% for the other CVOTs.
| DISCUSSION
With respect to prior MI,~20% of the general population was represented in LEADER and SUSTAIN-6, and~50% in REWIND.
Analysis of the potential generalizability of results from the same studies if all individuals in a general population who matched the entry criteria for each trial had been enrolled randomly suggested qualitatively similar but quantitatively more extreme patterns. Notably, when
I/E criteria for each trial were applied to the general population, Illustrates the percentage of T2D adult patients that fit all of the inclusion-exclusion criteria. See Table 1 for a description of these criteria. 
FIGURE 2 Generalizability of individual cardiovascular outcome trials inclusion-exclusion criteria
